Skip to main content

Table 2 Organ dysfunction, biological data and treatments during septic shock according to supraventricular arrhythmia occurrence

From: New-onset supraventricular arrhythmia during septic shock: prevalence, risk factors and prognosis

  Sinus rhythm (n = 41) SVA (n = 30) p
SOFA day 1
 Global (0–24) 10.0 [7.0–12.5] 10 [8–16] 0.369
 Neurological (0–4) 1.0 [0.0–4.0] 1.0 [0.0–4.0] 0.869
 Respiratory (0–4) 2.0 [0.0–4.0] 2.0 [0.8–3.0] 0.976
 Cardiovascular (0–4) 4.0 [4.0–4.0] 4.0 [4.0–4.0] 0.709
 Renal (0–4) 1.0 [0.0–2.5] 2.0 [1.0–4.0] 0.034
 Coagulation (0–4) 0.0 [0.0–1.5] 1.0 [0.0–2.0] 0.573
 Hepatic (0–4) 0.0 [0.0–2.0] 0.0 [0.0–1.25] 0.875
Day 1 blood gases
 pH 7.33 [7.21–7.41] 7.32 [7.24–7.40] 0.802
 PCO2, mmHg 37.0 [29.0–44.5] 36.0 [30.7–47.5] 0.692
 PO2, mmHg 123.0 [84.5–185.5] 102.0 [76.0–215.2] 0.802
 Bicarbonates, mmol/L 19.0 [15.9–25.2] 20.5 [17.0–25.0] 0.518
 Lactate, mmol/L 2.90 [1.43–4.30] 2.10 [1.40–3.60] 0.514
 FIO2, % 100 [55–100] 100 [70–100] 0.910
 PEEP, cmH2O 5 [5] 5 [5] 0.759
Thyroid stimulating hormone, µUI/L 0.94 [0.35–3.12] 1.04 [0.34–2.26] 0.694
Cardiac Troponin peak between day 1 and day 3, ng/L 44 [12.5–295] 157.5 [22.7–545.8] 0.222
NT proBNP peak between day 1 and day 3, pg/mL 8092 [2424–32,410] 15,522 [5987–46209] 0.229
Minimal potassium level during septic shock, mmol/L 3.3 [2.8–3.7] 3.2 [2.9–3.4] 0.571
Maximal potassium level during septic shock, mmol/L 4.6 [4.3–5.2] 4.5 [4.2–5.1] 0.771
Hemodynamic treatments
 Cumulative fluid balance during shock, mL 5358 [2401–9965] 4233 [3241–9682] 0.979
 Daily fluid balance during shock, mL/day 2285 [1554–3825] 1387 [1080–1859] 0.106
 Dobutamine use during shock 8.0 (19.5) 5 (16.7) 0.759
 Dobutamine maximal dose, µg/kg/mina 5.0 [5.0–13.8] 10.0 [5.0–12.5] 0.622
 Dobutamine maximal dose, µg/kg/min, mean (SD)a 7.8 (4.9) 9.0 (4.2)  
 Norepinephrine use during shock 40 (97.6) 29 (96.7) >0.99
 Norepinephrine maximal dose, mg/ha 2.9 [1.2–8.0] 3.3 [2.0–10.0] 0.210
 Norepinephrine maximal dose, mg/h, mean (SD)a 5.1 (5.5) 6.7 (6.4)  
 Epinephrine use during shock 3 (7.3) 3 (10.0) 0.692
 Dual catecholamine use during shock 10 (24.4) 6 (20.0) 0.662
 Length of catecholamine use during shock, days 3 [2–5] 4 [3–7] 0.035
 Length of vasopressor use during shock, days 3 [2–5] 4 [3–7.0] 0.021
Respiratory treatments
 Invasive mechanical ventilation 33 (80.5) 27 (90.0) 0.335
 Mild ARDS 7 (17.9) 7 (24.1) 0.532
 Moderate to severe ARDS 17 (41.5) 11 (36.7) 0.683
Other treatments
 Dialysis during shock 7 (17.1) 11 (36.7) 0.061
 Steroid use during shock 25 (61.0) 25 (83.3) 0.041
 Steroid use before SVA onset 25 (61.0) 14 (46.7) 0.231
Superior vena cava central line in place during shock 13 (31.7) 10 (33.3) 0.885
  1. Data are n (%) or median [25th–75th percentile] unless otherwise specified
  2. SVA supraventricular arrhythmia, SOFA sepsis-related organ failure assessment, PEEP positive end-expiratory pressure, ARDS acute respiratory distress syndrome
  3. aOnly patients receiving the drug during septic shock were considered